Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study

The coronavirus disease 2019 (COVID-19) severely hindered the timely receipt of health care for patients with cancer, especially female patients. Depression and anxiety were more pronounced in female patients than their male counterparts with cancer during treatment wait-time intervals. Herein, inve...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2022-12, Vol.20 (1), p.560-560, Article 560
Main Authors: Min, Yu, Liu, Zheran, Huang, Rendong, Li, Ruidan, Jin, Jing, Wei, Zhigong, He, Ling, Pei, Yiyan, Li, Ning, Su, Yongllin, Hu, Xiaolin, Peng, Xingchen
Format: Article
Language:English
Subjects:
Adenocarcinoma
Breast cancer
Breast Neoplasms
Cancer
Carcinoma, Non-Small-Cell Lung
Care and treatment
Cervical cancer
Cervix
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms
Coronaviruses
COVID-19
Epidemiology
Female
Female cancer
Females
Health aspects
Humans
Lung cancer
Lung Neoplasms
Male
Marital status
Non-small cell lung carcinoma
Patient outcomes
Patients
Risk factors
SEER
Small cell lung carcinoma
Survival
Thyroid cancer
Thyroid Neoplasms
Time-to-Treatment
Treatment delay intervals
Uterine Cervical Neoplasms
Women
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coronavirus disease 2019 (COVID-19) severely hindered the timely receipt of health care for patients with cancer, especially female patients. Depression and anxiety were more pronounced in female patients than their male counterparts with cancer during treatment wait-time intervals. Herein, investigating the impact of treatment delays on the survival outcomes of female patients with early-stage cancers can enhance the rational and precise clinical decisions of physicians. We analyzed five types of cancers in women from the Surveillance, Epidemiology, and End Results (SEER) program between Jan 2010 and Dec 2015. Univariate and multivariate Cox regression analyses were used to determine the impacts of treatment delays on the overall survival (OS) and cancer-specific survival (CSS) of the patients. A total of 241,661 females with early-stage cancer were analyzed (12,617 cases of non-small cell lung cancer (NSCLC), 166,051 cases of infiltrating breast cancer, 31,096 cases of differentiated thyroid cancer, 23,550 cases of colorectal cancer, and 8347 cases of cervical cancer). Worse OS rates were observed in patients with treatment delays ≥ 3 months in stage I NSCLC ( Hazard ratio (HR) = 1.11, 95% Confidence Interval (CI): 1.01-1.23, p = 0.044) and stage I infiltrating breast cancer ( HR = 1.23, 95% CI 1.11-1.37, p 
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-022-03719-7